Home | Tarsus
Oct 17, 2024 · Creating novel therapies, beginning with the eye XDEMVY ® (lotilaner ophthalmic solution) 0.25% is the first and only FDA-approved product for the millions of patients living with Demodex blepharitis.
Our Story - Tarsus
We are Tarsus – a biopharmaceutical company dedicated to creating new categories in eye care and beyond. We're driven by a deep commitment to serving patient needs and changing lives. We push boundaries to find new ways forward – for our …
News Release - Tarsus Pharmaceuticals
Jul 25, 2023 · Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis.
Demodex Blepharitis - Tarsus
Demodex blepharitis (DB) is a highly prevalent and underdiagnosed ocular disease that affects ~58% of eye care patients in the United States 1-3, *.
Xdemvy - Tarsus
XDEMVY ® is the first and only FDA-approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis. 1,2. Important Safety Information: Most common side effects: Most common side effect in clinical trials was stinging and burning in 10% patients.
TP-03 | Tarsus
Tarsus initiates phase 2a Ersa trial evaluating TP-03 for the treatment of meibomian gland disease. News release. Tarsus Pharmaceuticals, Inc. August 5, 2022. Accessed September 30, 2024. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-treatment 2.
Our Leadership - Tarsus
Tarsus secured FDA approval for its first product, XDEMVY ® (lotilaner ophthalmic solution) 0.25%, which is the first and only FDA-approved treatment in the United States for the eyelid disease Demodex blepharitis. Beyond XDEMVY, Tarsus continues to advance its pipeline into Phase 2 clinical studies, evaluating therapies that have the ...
Tarsus Launches “Your Mitey Problem,” the First Direct-to …
Oct 17, 2024 · The first-of-its-kind campaign, called “Your Mitey Problem,” provides viewers with an inside look at a Demodex mite ‘party’ taking place on a patient’s eyelids. The uninvited eyelid squatters are feasting on oily sebum, clawing onto eyelashes and leaving behind a trail of waste, eyelid redness and inflammation.
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye …
Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying two investigational medicines in clinical trials.
Tarsus Announces Positive Topline Results from the Ersa Phase 2a ...
Dec 11, 2023 · Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis.
- Some results have been removed